Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Patriarca

Showing results (61-70 of 156) with videos related to

Pageof 16
Sort By:
European Journal of Haematology|March 26, 2014
Experts' considerations on HLA-haploidentical stem cell transplantationFrancesca Patriarca, Leo Luznik, Marta Medeot, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 24, 2018
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO GroupFrancesca Patriarca, Arianna Masciulli, Andrea Bacigalupo, et al.
Blood|October 25, 2013
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHDAttilio Olivieri, Michele Cimminiello, Paolo Corradini, et al.
Haematologica|April 12, 2008
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpuraFrancesco Zaja, Marta Lisa Battista, Maria Teresa Pirrotta, et al.
European Journal of Haematology|March 3, 2007
Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myelomaBenedetto Bruno, Roberto Sorasio, Francesca Patriarca, et al.
The New England Journal of Medicine|March 16, 2007
A comparison of allografting with autografting for newly diagnosed myelomaBenedetto Bruno, Marcello Rotta, Francesca Patriarca, et al.
Cancer|June 28, 2021
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma NetworkFrancesca Gay, Andreas Günther, Massimo Offidani, et al.
Hemasphere|October 7, 2022
Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple MyelomaPieter Sonneveld, Sonja Zweegman, Michele Cavo, et al.
Leukemia & Lymphoma|June 1, 2010
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approachesMonika Engelhardt, Martina Kleber, Josefina Udi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2007
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical studyMichele Cavo, Patrizia Tosi, Elena Zamagni, et al.
Pageof 16

Showing results (61-70 of 156) with videos related to

Sort By:
Pageof 16
European Journal of Haematology|March 26, 2014
Experts' considerations on HLA-haploidentical stem cell transplantationFrancesca Patriarca, Leo Luznik, Marta Medeot, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 24, 2018
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO GroupFrancesca Patriarca, Arianna Masciulli, Andrea Bacigalupo, et al.
Blood|October 25, 2013
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHDAttilio Olivieri, Michele Cimminiello, Paolo Corradini, et al.
Haematologica|April 12, 2008
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpuraFrancesco Zaja, Marta Lisa Battista, Maria Teresa Pirrotta, et al.
European Journal of Haematology|March 3, 2007
Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myelomaBenedetto Bruno, Roberto Sorasio, Francesca Patriarca, et al.
The New England Journal of Medicine|March 16, 2007
A comparison of allografting with autografting for newly diagnosed myelomaBenedetto Bruno, Marcello Rotta, Francesca Patriarca, et al.
Cancer|June 28, 2021
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma NetworkFrancesca Gay, Andreas Günther, Massimo Offidani, et al.
Hemasphere|October 7, 2022
Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple MyelomaPieter Sonneveld, Sonja Zweegman, Michele Cavo, et al.
Leukemia & Lymphoma|June 1, 2010
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approachesMonika Engelhardt, Martina Kleber, Josefina Udi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2007
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical studyMichele Cavo, Patrizia Tosi, Elena Zamagni, et al.
Pageof 16